Tirzepatide causes weight loss through several overlapping mechanisms: it suppresses appetite by acting on hunger-regulating neurons in the brain, slows the rate at which your stomach empties after meals, and changes how your body stores and releases fat. What makes it distinct from older weight loss medications is that it activates two gut hormone receptors simultaneously, producing greater weight loss than drugs targeting just one. In clinical trials, people lost between 15% and 21% of their body weight over 72 weeks, depending on the dose.
Two Receptors Instead of One
Your gut naturally produces two hormones after you eat: GLP-1 and GIP. Both signal to your brain and pancreas that food has arrived, but they do so through separate receptor pathways. Older medications like semaglutide activate only the GLP-1 receptor. Tirzepatide activates both.
This dual action isn’t just additive. The drug’s affinity for the GIP receptor matches that of natural GIP, while its interaction with the GLP-1 receptor is about fivefold weaker than natural GLP-1. That imbalance turns out to be an advantage: tirzepatide activates the GLP-1 receptor in a way that causes less desensitization over time, meaning the receptor keeps responding to the drug rather than becoming numb to it. In a head-to-head trial against semaglutide (the highest approved dose), all three doses of tirzepatide produced greater weight loss.
How It Changes Hunger Signals in the Brain
The hypothalamus, a region deep in your brain, contains a cluster of neurons called AgRP neurons that function like a starvation alarm. When your body loses weight and enters a negative energy balance, these neurons ramp up activity, driving you to eat more. This is one reason dieting is so hard to sustain: as you lose weight, your brain actively pushes back.
Tirzepatide attacks this problem from two directions. First, it activates neurons in the brainstem that signal fullness after a meal, the same way natural gut hormones do but with a much stronger, longer-lasting effect. Second, it silences those AgRP hunger neurons that would normally become more active as weight drops. As one Northwestern University researcher described it, the drug creates a “double whammy” where appetite is suppressed and the rebound hunger that typically accompanies weight loss is blocked.
Surprisingly, the GIP component of tirzepatide, not the GLP-1 component, appears to be essential for communicating meal signals to AgRP neurons. GIP receptors aren’t actually located on AgRP neurons themselves, so this effect works through an indirect circuit that researchers are still mapping. But the practical result is clear: the GIP pathway adds a layer of appetite control that GLP-1-only drugs don’t provide.
Slower Stomach Emptying
Tirzepatide delays gastric emptying, meaning food stays in your stomach longer after a meal. This contributes to feeling full sooner and staying full longer. The effect is most pronounced after the first dose and partially diminishes with subsequent doses as the body adjusts, a process called tachyphylaxis. Still, the delay in gastric emptying is greater with tirzepatide than with GLP-1-only drugs, which contributes to its stronger overall effect on food intake.
Changes in Fat Metabolism
The GIP receptor isn’t just active in the brain and gut. It’s also present on fat cells, and tirzepatide’s activation of this receptor changes how your body handles fat in ways that go beyond simply eating less.
When insulin is present (after eating), GIP receptor activation helps fat cells absorb glucose and clear fatty acids from the bloodstream more efficiently. It also increases the conversion of glucose into glycerol, a building block for fat storage. That might sound counterproductive, but the net effect is healthier fat tissue that processes nutrients more effectively rather than letting lipids circulate in the blood where they cause metabolic damage. During fasting, when insulin levels are low, GIP receptor activation flips the script and promotes lipolysis, the release of stored fat for energy. In animal studies, a long-acting GIP receptor activator reduced circulating triglyceride levels during fat-heavy meals and improved uptake of dietary fat into adipose tissue. Separately, GIP receptor activation has been shown to improve insulin sensitivity through a mechanism independent of weight loss itself.
Clinical Weight Loss Results
The SURMOUNT-1 trial tested tirzepatide in adults with obesity (without diabetes) over 72 weeks. The results, compared to a 3.1% loss in the placebo group:
- 2.5 mg starting dose, titrated to 5 mg: 15% body weight loss
- 10 mg dose: 19.5% body weight loss
- 15 mg dose: 20.9% body weight loss
For context, a person weighing 250 pounds on the highest dose would lose roughly 52 pounds on average over that period. In the SURPASS-2 trial, which compared tirzepatide directly to semaglutide in people with type 2 diabetes, weight loss was significantly greater with tirzepatide at every dose tested, increasing in a linear fashion with each step up.
How Dosing Works
Tirzepatide is a once-weekly injection that starts at 2.5 mg and increases by 2.5 mg every four weeks, up to a maximum of 15 mg. This gradual titration exists primarily to manage gastrointestinal side effects, which are most common early in treatment. Over 80% of gut-related side effects occur within the first three months, with a median onset of just 16 days. The most common issues are nausea (reported in about 28% of cases), diarrhea (13%), vomiting (11%), constipation (8%), and upper abdominal pain (5%). These tend to ease as the body adjusts and the dose stabilizes.
What Happens After Stopping
Weight regain after discontinuation is significant. The SURMOUNT-4 trial tracked participants who stopped tirzepatide after an initial weight loss period. One year after switching to placebo, 82% of participants regained more than a quarter of the weight they had lost. Roughly a third regained 50% to 75% of their lost weight, and about a quarter regained 75% or more. This pattern reflects the fact that tirzepatide doesn’t permanently reset the brain’s weight regulation system. The appetite-suppressing effects, the slowed gastric emptying, the metabolic changes in fat tissue all depend on the drug’s continued presence. Once it’s removed, the biological drives that promote weight regain reassert themselves, particularly those AgRP hunger neurons that the drug was actively silencing.